🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 2 días
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
13/04/2015 0,5100 USD
13/01/2015 0,4900 USD
10/10/2014 0,4200 USD
11/07/2014 0,4200 USD
11/04/2014 0,4200 USD
13/01/2014 0,4000 USD
10/10/2013 0,4000 USD
11/07/2013 0,4000 USD
11/04/2013 0,4000 USD
11/01/2013 0,4000 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
31/01/2018 116,21 116,50 111,29 112,22 -3,16% 4,48% 15.744.800
30/01/2018 119,42 121,45 115,87 115,88 -5,26% 4,67% 11.851.400
29/01/2018 121,50 124,15 118,98 122,31 -0,73% 4,26% 10.182.700
26/01/2018 114,50 125,86 113,50 123,21 +13,77% 10,79% 19.614.500
25/01/2018 105,95 108,37 105,74 108,30 +2,64% 2,48% 6.327.500
24/01/2018 105,26 106,23 104,10 105,51 +0,12% 2,02% 4.436.500
23/01/2018 106,17 106,97 105,03 105,38 -1,04% 1,83% 5.095.300
22/01/2018 104,70 106,54 104,46 106,49 +1,77% 1,99% 4.538.100
19/01/2018 104,33 104,87 103,55 104,64 +0,80% 1,27% 4.991.300
18/01/2018 104,29 104,85 103,44 103,81 -0,53% 1,35% 6.371.200
17/01/2018 103,00 104,84 102,55 104,36 +1,82% 2,22% 5.384.900
16/01/2018 100,26 103,00 100,00 102,49 +2,14% 2,99% 8.528.600
12/01/2018 99,34 100,64 98,66 100,34 +1,08% 1,99% 4.372.600
11/01/2018 99,37 99,49 98,56 99,27 -0,42% 0,94% 4.240.900
10/01/2018 99,65 100,20 99,18 99,69 -0,55% 1,02% 4.608.600
09/01/2018 99,49 100,66 98,70 100,24 +0,75% 1,97% 4.055.400
08/01/2018 101,28 101,28 98,18 99,49 -1,60% 3,06% 5.582.000
05/01/2018 99,34 101,20 98,56 101,11 +1,74% 2,66% 4.599.300
04/01/2018 100,07 100,12 98,35 99,38 -0,57% 1,77% 3.579.000
03/01/2018 98,55 100,10 98,04 99,95 +1,56% 2,09% 4.702.300
02/01/2018 97,14 98,90 96,75 98,41 +1,76% 2,21% 4.561.300
29/12/2017 98,14 98,43 96,71 96,71 -1,10% 1,75% 3.214.400
28/12/2017 98,19 98,39 97,52 97,79 -0,31% 0,89% 1.870.400
27/12/2017 97,73 98,23 97,44 98,09 +0,35% 0,81% 1.927.300
26/12/2017 98,15 98,36 97,05 97,75 -0,47% 1,33% 2.363.800
22/12/2017 97,86 98,69 97,71 98,21 +0,31% 1,00% 2.835.600
21/12/2017 97,82 98,35 97,72 97,91 +0,51% 0,64% 2.249.500
20/12/2017 97,86 98,90 97,22 97,41 -0,52% 1,72% 3.411.900
19/12/2017 98,42 98,55 97,70 97,92 -0,27% 0,86% 2.817.700
18/12/2017 97,67 99,10 97,55 98,19 +0,76% 1,59% 4.768.300